Two target regions of allelic loss on chromosome 9 in urinary-bladder cancer

Japanese Journal of Cancer Research

Volumn 90, Issue 9, 1999, Pages 957-964

  Ohgaki, Kenji ^a   Minobe, Kaori ^a   Kurose, Keisuke ^a   Iida, Aritoshi ^a   Habuchi, Tomonori ^b   Ogawa, Osamu ^b   Kubota, Yoshinobu ^c   Akimoto, Masao ^a   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Chromosome 9; Loss of heterozygosity; Tumor suppressor gene; Urinary bladder cancer

Indexed keywords

MICROSATELLITE DNA;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER GENETICS; CHROMOSOME 9; CONTROLLED STUDY; DNA FLANKING REGION; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENE LOSS; GENE MAPPING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0032726398     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00841.x     Document Type: Article

References (52)

1. Nakamura, Y. Application of DNA markers to clinical genetics. Jpn. J. Hum. Genet., 41, 1-14 (1996).
2. Olumi, A. F., Tsai, Y. C., Nichols, P. W., Skinner, D. G., Cain, D. R., Bender, L. I. and Jones, P. A. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell cancers of the bladder. Cancer Res., 50, 7081-7083 (1990).
3. Knowles, M. A., Shaw, M. E. and Proctor, A. J. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene, 8, 1357-1364 (1993).
4. Brewster, S. F., Gingell, J. C., Browne, S. and Brown, K. W. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell cancer of the bladder. Br. J. Cancer, 70, 697-700 (1994).
5. Devlin, J., Keen, A. J. and Knowles, M. A. Homozygous deletion mapping at 9p21 in bladder cancer defines a critical region within 2 cM of IFNA. Oncogene, 9, 2757-2760 (1994).
6. Habuchi, T., Devlin, J., Elder, P. A. and Knowles, M. A. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene, 11, 1671-1674 (1995).
7. Shaw, M. E. and Knowles, M. A. Deletion mapping of chromosome 11 in cancer of the bladder. Genes Chromosom. Cancer, 13, 1-8 (1995).
8. Takle, L. A. and Knowles, M. A. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene, 12, 1083-1087 (1996).
9. Kagan, J., Liu, J., Stein, J. D., Wagner, S. S., Babkowski, R., Grossman, B. H. and Katz, R. L. Cluster of allelic losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene, 16, 909-913 (1998).
10. Castellano, M. C., Pollock, P. M., Walters, M. K., Sparrow, L. E., Down, L. M., Gabrielli, B. G., Parsons, P. G. and Hayward, N. K. CDKN2A/CDKN2 is inactivated in most melanoma cell lines. Cancer Res., 57, 4868-4875 (1997).
11. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., 3rd, Johnson, B. E. and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
12. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756 (1994).
13. Mori, T., Miura, K., Aoki, T., Nishihara, T., Mori, S. and Nakamura, Y. Frequent somatic mutation of the MTS/ CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell cancer. Cancer Res., 54, 3396-3397 (1994).
14. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hrubun, R. H., Yeo, C. J. and Kern, S. E. Frequent somatic mutations and homozygous deletions of the CDKN2 (MST1) gene in pancreatic adenocancer. Nat. Genet., 8. 27-32 (1994).
15. Gonzalez-Zulueta, M., Shibata, A., Ohneseit, P. F., Spruck, C. H., III, Busch, C., Shamaa, M., El-Baz, M., Nichols, P. W., Gonzalgo, M. L. and Elbaz, M. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell cancer of the bladder. J. Natl. Cancer. Inst., 87, 1383-1393 (1995).
16. Hahn, H., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K., Smyth, I., Pressman, C., Leffell, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Toftgard, R., Chenevix-Trench, G., Wainwright, B. and Bale, A. E. Mutations of the human homolog of Drosophila patched in the nevoid basal cell cancer syndrome. Cell, 85, 841-851 (1996).
17. Xie, J., Johnson, R. I., Zhang, X., Bare, J. W., Waldman, F. M., Cogen, P. H., Menon, A. G., Warren, R. S., Chen, L. C., Scott, M. P. and Epstein, E. H., Jr. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res., 57, 2369-2372 (1997).
18. Habuchi, T., Yoshida, O. and Knowles, M. A. A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Hum. Mol. Genet., 6, 913-919 (1997).
19. Okamura, S., Koyama, K., Miyoshi, Y., Monden, M. and Takami, M. Novel germline mutations of hMSH2 in a patient with hereditary nonpolyposis colorectal cancer (HNPCC) and in a patient with six primary cancers. J. Hum. Genet., 43, 143-145 (1998).
20. Buetow, K. H., Weber, J. L., Lundwigsen, S., Scherpbier-Heddeme, T., Duyk, G. M. and Scheffield, V. C. Integrated human genome-wide maps constructed using the CEPH reference panel. Nat. Genet., 6, 391-393 (1994).
21. Gyapay, G., Morissette, J., Vignal, A., Dib, C., Fizames, C. and Millasseau, P. The 1993-94 Généthon human genetic linkage map. Nat. Genet., 7, 246-339 (1994).
22. Nakura, J., Miki, T., Ye, L., Mitsuda, N., Ogihara, T., Ohta, T., Jinno, Y., Niikawa, N., Takahashi-Fujii, A. and Ishino, Y. Six dinucleotide repeat polymorphisms on chromosome 7. Jpn. Hum. Genet., 39, 447-449 (1994).
23. Hirayama, T., Yamaki, E., Hata, A., Tsuji, M., Hashimoto, K., Yamamoto, M. and Emi, M. Five familial hypercholesterolemic kindreds in Japan with novel mutations of the LDL receptor gene. J. Hum. Genet., 43, 250-254 (1998).
24. World Health Organization. "In Histological Classification of Tumors No. 10" (1973). WHO, Geneva.
25. "Union Internationale Contre le Cancer," 3rd Ed. (1978). International Union against Cancer, Geneva.
26. Ruppert, J. M., Tokino, K. and Sidransky, D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res., 53, 5093-5095 (1993).
27. Cairns, P., Tokino, K., Eby, Y. and Sidransky, D. Homozygous deletion of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res., 54, 1422-1424 (1994).
28. Orlow, I., Lianes, P., Lacombe, L., Dalbagni, G., Reuter, V. E. and Cordon-Cardo, C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res., 54, 2848-2851 (1994).
29. Keen, A. J. and Knowles, M. A. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene, 9, 2083-2088 (1994).
30. Simoneau, A. R., Spruck, C. H., 3rd, Gonzalez-Zulueta, M., Gonzalgo, M. L., Chan, M. F., Tsai, Y. C., Dean, M., Steven, K., Horn, T. and Jones, P. A. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res., 56, 5039-5043 (1996).
31. Czerniak, B., Chaturvedi, V., Li, L., Hodges, S., Johnston, D., Roy, J. Y., Luthra, R., Logothetis, C., Von Eschenbach, A. C., Grossman, H. B., Benedict, W. F. and Batsakis, J. G. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene, 18, 1185-1196 (1999).
32. Stadler, W. M., Sherman, J., Bohlander, S. K., Roulston, D., Dreyling, M., Rukstails, D. and Olopad, O. I. Homozygous deletion within chromosomal bands 9p21-22 in bladder cancer. Cancer Res., 54, 2060-2063 (1994).
33. Orlow, I., Lacombe, L., Hannon, G. J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V. E., Zhang, Z. F., Beach, D. and Cordon-Cardo, C. Deletion of the CDKN2 and p15 genes in human bladder tumors. J. Natl. Cancer Inst., 87, 1524-1529 (1995).
34. Williamson, M. P., Elder, P. A., Shaw, M. E., Devlin, J. and Knowles, M. A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet., 4, 1569-1577 (1995).
35. Bjorkqvist, A. M., Tammilehto, L., Anttili, S., Mattson, K. and Knuutila, S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br. J. Cancer, 75, 523-527 (1997).
36. Cairns, P., Tokino, K., Eby, Y. and Sidransky, D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell cancers. Cancer Res., 55, 224-227 (1995).
37. Merlo, A., Gabrielson, E., Askin, F. and Sidransky, D. Frequent loss of chromosome 9p in human primary non-small cell lung cancer. Cancer Res., 54, 640-642 (1994).
38. Huang, D. P., Lo, K. W., van Hasselt, C. A., Woo, J. K. S., Choi, P. H. K., Leung, S. F., Cheung, S. T., Cairns, P., Sidransky, D. and Lee, J. C. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal cancer. Cancer Res., 54, 4003-4006 (1994).
39. van der Reit, P., Nawroz, H., Hruban, R. H., Corio, R., Tokino, K., Koch, W. and Sidransky, D. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res., 54, 1156-1158 (1994).
40. An, H. X., Niederacher, D., Picard, F., van Roeyen, C., Bender, H. G. and Beckmann, M. W. Frequent allele loss on 9p21-22 defines a smallest common region in vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosom. Cancer, 17, 14-20 (1996).
41. Baud, E., Catilina, P. and Bignon, Y. J. p16 involvement in primary bladder tumors: analysis of deletions and mutations. Int. J. Oncol, 14, 441-445 (1999).
42. Benedict, W. F., Lerner, S. P., Zhou, L, Shen, X., Tokunaga, H. and Czerniak, B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/ CDKN2) status in bladder cancer. Oncogene, 18, 1197-1203 (1999).
43. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A. and Read, J. C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell, 80, 279-284 (1995).
44. Simoneau, M., Aboulkassim, T. O., LaRue, H., Rousseau, F. and Fradet, Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene, 18, 157-163 (1999).
45. Habuchi, T., Luscombe, M., Elder, P. A. and Knowles, M. A. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics, 48, 277-288 (1998).
46. Suzuki, K., Daigo, Y., Fukuda, S., Tokino, T., Isomura, M., Isono, K., Wainwright, B. and Nakamura, Y. No evidence of mutation in the human PTC gene, responsible for nevoid basal cell carcinoma syndrome, in human primary squamous cell carcinomas of the esophagus and lung. Jpn. J. Cancer Res., 88, 225-228 (1997).
47. McGarvey, T. W., Maruta, Y., Tomaszewski, J. E., Linnenbach, A. J. and Malkowicz, S. B. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene, 17, 1167-1172 (1998).
48. Vellucci, V. F. and Reiss, M. Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene. Genomics, 46, 278-283 (1997).
49. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J., Burley, M., Jeremiah, S., Woodward, K., Nahmias, J., Fox, M., Ekong, R., Osborne, J., Wolfe, J., Povey, S., Snell, R. G., Cheadle, J. P., Jones, A. C., Tachataki, M., Ravine, D. and Kwiatkowski, D. J. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277, 805-808 (1997).
50. Feinstein, E., Druck, T. and Kastury, K. Assignment of DAP1 and DAPK - genes that positively mediate programmed cell death triggered by IFN-γ - to chromosome regions 5p12.2 and 9q34.1, respectively. Genomics, 29, 305-307 (1995).
51. Cairns, P., Shaw, M. E. and Knowles, M. A. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene, 8, 1083-1085 (1993).
52. Miyao, N., Tsai, Y. C., Lerner, S. P., Olumi, A. F., Spruck, C. H., III, Gonzalez-Zulueta, M., Nichols, P. W., Skinner, D. G. and Jones, P. A. Role of chromosome 9 in human bladder cancer. Cancer Res., 53, 4066-4070 (1993).